T Shukuya

Summary

Affiliation: Juntendo University School of Medicine
Country: Japan

Publications

  1. doi request reprint Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients
    Takehito Shukuya
    Divisions of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan Divisions of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan Electronic address
    Respir Investig 52:101-6. 2014
  2. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
  3. doi request reprint Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 43:176-83. 2013
  4. doi request reprint Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi chou, Suntou gun, Shizuoka, Japan
    Lung Cancer 74:457-61. 2011
  5. doi request reprint Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    Cancer Sci 102:1032-7. 2011
  6. ncbi request reprint Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease
    T Shukuya
    Department of Respiratory Medicine, Juntendo University, School of Medicine, Bunkyou ku, Tokyo, Japan
    Anticancer Res 30:4357-61. 2010
  7. ncbi request reprint Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer
    Minehiko Inomata
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 31:4519-23. 2011
  8. ncbi request reprint Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka, 411 8777, Japan
    Anticancer Res 32:675-80. 2012
  9. doi request reprint Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study
    Takehito Shukuya
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 40:1135-8. 2010
  10. doi request reprint Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi cho, Suntou gun, Shizuoka, 411 8777, Japan
    Med Oncol 27:932-7. 2010

Collaborators

Detail Information

Publications11

  1. doi request reprint Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients
    Takehito Shukuya
    Divisions of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan Divisions of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan Electronic address
    Respir Investig 52:101-6. 2014
    ..This study aimed at evaluating the efficacy of cisplatin plus pemetrexed and comparing it with that of cisplatin plus gemcitabine in Japanese MPM patients...
  2. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
    ..The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS...
  3. doi request reprint Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 43:176-83. 2013
    ....
  4. doi request reprint Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi chou, Suntou gun, Shizuoka, Japan
    Lung Cancer 74:457-61. 2011
    ....
  5. doi request reprint Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
    Cancer Sci 102:1032-7. 2011
    ..000028; DCR: 67-70%vs 92-93%, P = 0.000014; mPFS: 3.0 vs 9.4 months, P = 0.0001, respectively). Gefitinib is less effective in non-adenocarcinoma NSCLC harboring EGFR mutations than adenocarcinoma harboring EGFR mutations...
  6. ncbi request reprint Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease
    T Shukuya
    Department of Respiratory Medicine, Juntendo University, School of Medicine, Bunkyou ku, Tokyo, Japan
    Anticancer Res 30:4357-61. 2010
    ..Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients...
  7. ncbi request reprint Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer
    Minehiko Inomata
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 31:4519-23. 2011
    ..We retrospectively evaluated the clinical course of patients who received continuous administration of EGFR-TKIs after disease progression was detected solely in bone lesions...
  8. ncbi request reprint Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi chou, Suntou gun, Shizuoka, 411 8777, Japan
    Anticancer Res 32:675-80. 2012
    ..However, there have been no studies that have compared S-1 and CDDP combined with thoracic radiotherapy (TRT) with VNR and CDDP combined with TRT...
  9. doi request reprint Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study
    Takehito Shukuya
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411 8777, Japan
    Jpn J Clin Oncol 40:1135-8. 2010
    ..The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study...
  10. doi request reprint Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi cho, Suntou gun, Shizuoka, 411 8777, Japan
    Med Oncol 27:932-7. 2010
    ....
  11. ncbi request reprint Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib
    Takehito Shukuya
    Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou gun, Shizuoka 411 8777, Japan
    Anticancer Res 29:2747-51. 2009
    ..New therapeutic modalities are needed for non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to gefitinib...